Transsexualism and osteoporosis
Schlatterer K, Auer DP, Yassouridis A, von Werder K, Stalla GK.
Dept. of Endocrinology, Max Planck Institute of Psychiatry, Munich, Germany.
Abstract [Full Text] [PDF]
The aim of this study was to investigate whether and to what extent our regime of cross-gender hormone replacement therapy might influence osteoporosis development in transsexual patients.
We found that after long-term therapy the bone densities of our cross-gender hormone-treated transsexual groups (10 male-to-female and 10 female-to-male) did not show significant differences compared to those of the corresponding biological sex. Moreover, the bone-density during therapy pointed out very little variability and that independent of the gender-alteration (transsexuality-direction) and the age of the transsexuals.
Our results indicate that for transsexual patients treated with cross-gender hormone replacement therapy the risk of developing osteoporosis is low.
Citation: Clin Endocrinol Diabetes 1998;106(4):365-8 an article published on the Internet by PubMed <http://www.ncbi.nlm.nih.gov/>